Table 3. Univariate analysis.

Outcome	Tregs/CD4+ T cells	All patients (n=94)			T-replete (n=36)			T-deplete (n=58)
		%	95% CI	P-value	%	95% CI	P-value	%	95% CI	P-value
Neutrophil recovery (day 30)	<0.0296	87	73–94		92	34–99		86	68–94
				0.046			0.33			0.02
	>0.0296	98	64–100		96	34–100		100	100–100
Platelet recovery (day 60)	<0.0296	87	73–94		100	100–100		83	65–92
				0.03			0.45			0.02
	>0.0296	98	67–100		96	43–100		100	100–100
Lymphocyte recovery (day 180)	<0.0296	61	45–73		92	33–99		59	31–64
				0.001			0.64			0.004
	>0.0296	83	68–92		92	64–98		70	45–85
CMV activation (1 year)	<0.0296	45	30–59		42	14–68		46	29–61
				0.89			0.99			0.74
	>0.0296	45	30–58		42	22–61		48	26–67
Acute GvHD (day 100)	<0.0296	38	25–52		42	14–68		37	21–53
				0.11			0.13			0.51
	>0.0296	23	13–36		17	5.0–34		30	13–50
Chronic GvHDa (3 years)	<0.0296	74	56–85		80	36–96		71	50–85
				0.79			0.51			0.79
	>0.0296	74	58–85		77	52–90		71	45–87
Relapse (3 years)	<0.0296	25	13–38		17	2–43		28	14–44
				0.80			0.70			0.83
	>0.0296	23	12–36		21	7–39		26	10–35
Non-relapse mortality (3 years)	<0.0296	35	21–49		33	9–60		35	20–51
				0.02			0.16			0.07
	>0.0296	13	5–24		13	3–29		13	3–30
Overall survival (3 years)	<0.0296	49	37–66		50	28–88		49	35–68
				0.02			0.20			0.07
	>0.0296	75	63–88		71	55–92		78	63–97

Abbreviations: CI=confidence interval; Tregs=regulatory T cells.

Low Tregs/CD4⁺ T cells (<0.0296); high Tregs/CD4⁺ T cells (>0.0296).

^aOnly patients with survival >100 days (n=83).

Significant variables (P<0.05) shown in bold.